Amgen Expands Data Demands From Providers Getting Drug Discounts

Amgen Inc. is planning to require that all health providers under a federal drug discount plan submit claims data for dispensing of the company’s medicines, joining other manufacturers in imposing policies that seek to rein in the program’s growth.

The policy, slated to go into effect June 1, demands that all covered entities under the 340B Drug Pricing Program submit claims-level data for all medicines purchased from Amgen. The company is the latest manufacturer to propose a plan to minimize diversion and duplicate discounts under the program.

“We’re doing this to increase transparency and program integrity,” Kave Niksefat, senior ...